Kiniksa Pharmaceuticals (NASDAQ:KNSA) PT Raised to $30.00

Kiniksa Pharmaceuticals (NASDAQ:KNSA) had its price objective boosted by JPMorgan Chase & Co. from $26.00 to $30.00 in a report published on Wednesday morning, Benzinga reports. The firm currently has an overweight rating on the stock.

Several other research analysts have also weighed in on KNSA. TheStreet upgraded Kiniksa Pharmaceuticals from a d+ rating to a c rating in a research report on Thursday, February 29th. Evercore ISI upped their target price on shares of Kiniksa Pharmaceuticals from $25.00 to $30.00 and gave the company an outperform rating in a research report on Wednesday, April 24th. Finally, Wedbush restated an outperform rating and issued a $30.00 price objective on shares of Kiniksa Pharmaceuticals in a report on Tuesday, April 23rd.

Kiniksa Pharmaceuticals Stock Performance

NASDAQ KNSA opened at $19.40 on Wednesday. The stock’s fifty day moving average is $19.17 and its two-hundred day moving average is $18.06. The firm has a market capitalization of $1.37 billion, a P/E ratio of 176.38 and a beta of 0.32. Kiniksa Pharmaceuticals has a fifty-two week low of $11.01 and a fifty-two week high of $22.09.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, April 23rd. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.11). The firm had revenue of $79.90 million during the quarter, compared to analysts’ expectations of $76.97 million. Kiniksa Pharmaceuticals had a net margin of 2.78% and a negative return on equity of 7.26%. The company’s revenue for the quarter was up 65.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.18) EPS. As a group, sell-side analysts forecast that Kiniksa Pharmaceuticals will post -0.04 EPS for the current year.

Insider Transactions at Kiniksa Pharmaceuticals

In related news, CEO Sanj K. Patel sold 12,742 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $21.49, for a total transaction of $273,825.58. Following the completion of the transaction, the chief executive officer now directly owns 70,594 shares of the company’s stock, valued at approximately $1,517,065.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CAO Michael R. Megna sold 9,659 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $21.45, for a total transaction of $207,185.55. Following the completion of the transaction, the chief accounting officer now owns 17,588 shares in the company, valued at $377,262.60. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Sanj K. Patel sold 12,742 shares of the firm’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $21.49, for a total value of $273,825.58. Following the completion of the sale, the chief executive officer now owns 70,594 shares in the company, valued at $1,517,065.06. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 33,109 shares of company stock valued at $709,929. 54.23% of the stock is currently owned by company insiders.

Institutional Trading of Kiniksa Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. grew its position in Kiniksa Pharmaceuticals by 349.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,097 shares of the company’s stock worth $72,000 after purchasing an additional 3,186 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in Kiniksa Pharmaceuticals by 59.9% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 256,932 shares of the company’s stock worth $4,463,000 after purchasing an additional 96,288 shares during the period. Principal Financial Group Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals in the 3rd quarter valued at approximately $777,000. Alps Advisors Inc. grew its holdings in Kiniksa Pharmaceuticals by 38.3% during the third quarter. Alps Advisors Inc. now owns 71,103 shares of the company’s stock worth $1,235,000 after acquiring an additional 19,709 shares during the period. Finally, SG Americas Securities LLC purchased a new position in Kiniksa Pharmaceuticals in the fourth quarter worth $311,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.